MedTrace Logo

Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis

NCT01038739 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 330

Last updated 2017-07-21

No results posted yet for this study

Summary

The purpose of the study is to determine which dose of mesalazine granules compared to placebo is more effective in the prevention of recurrence of disease.

Conditions

  • Diverticulitis

Interventions

DRUG

Mesalazine

3 g per day

DRUG

Mesalazine

1.5 g per day

DRUG

Placebo

0 g per day

Sponsors & Collaborators

  • Dr. Falk Pharma GmbH

    lead INDUSTRY

Principal Investigators

  • Wolfgang Kruis, Professor · Evang. Krankenhaus Kalk, Medical department

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01038739 on ClinicalTrials.gov